These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
63 related articles for article (PubMed ID: 8962175)
1. Suppression of allorecognition by use of synthetic peptides. Colovai AI; Renna-Molajoni E; Cocciolo PL; Tugulea S; Liu Z; Harris PE; Suciu-Foca N; Cortesini R Transplant Proc; 1996 Dec; 28(6):3029-31. PubMed ID: 8962175 [No Abstract] [Full Text] [Related]
2. The inhibitory effect of altered collagen II peptide on HLA-DRB1-restricted T-cell activation. Cheng YJ; Zhou Q; Li ZG Scand J Immunol; 2005 Mar; 61(3):260-5. PubMed ID: 15787743 [TBL] [Abstract][Full Text] [Related]
3. [The accessory cell function of human alveolar macrophages in antigen-induced T-lymphocyte proliferative responses]. Ohtsuka M; Yoshizawa Y; Naitou T; Takahashi N; Kameyama M; Satou H; Suyama T; Fukuda K; Satou T; Yano H Nihon Kyobu Shikkan Gakkai Zasshi; 1988 Jul; 26(7):745-50. PubMed ID: 3266519 [No Abstract] [Full Text] [Related]
4. Rules governing peptide-class II MHC molecule interactions. Hammer J; Nagy ZA; Sinigaglia F Behring Inst Mitt; 1994 Jul; (94):124-32. PubMed ID: 7998906 [No Abstract] [Full Text] [Related]
5. NY-ESO-1 encodes DRB1*0401-restricted epitopes recognized by melanoma-reactive CD4+ T cells. Zarour HM; Storkus WJ; Brusic V; Williams E; Kirkwood JM Cancer Res; 2000 Sep; 60(17):4946-52. PubMed ID: 10987311 [TBL] [Abstract][Full Text] [Related]
6. Oncogene-derived peptides: a new class of tumor rejection antigens? Gedde-Dahl T; Olsen BH; Thorsby E; Gaudernack G Transplant Proc; 1993 Feb; 25(1 Pt 2):1385-6. PubMed ID: 8442151 [No Abstract] [Full Text] [Related]
7. Recognition by class II alloreactive T cells of processed determinants from human serum proteins. Panina-Bordignon P; Corradin G; Roosnek E; Sette A; Lanzavecchia A Science; 1991 Jun; 252(5012):1548-50. PubMed ID: 1710827 [TBL] [Abstract][Full Text] [Related]
8. T cells specific for viral antigens presented by HLA-Dw4 recognize DR13 on allogeneic cells: a possible mechanism for induction of rejection. Gjertsen HA; Lundin KE; Hansen T; Thorsby E Transplant Proc; 1993 Feb; 25(1 Pt 1):70-1. PubMed ID: 8382384 [No Abstract] [Full Text] [Related]
9. DR beta peptides block the antigen-specific response but not the alloresponse of a dual-reactive T-cell clone. Ulrich RG; Thomas JW; Miller GG; Atassi MZ Immunol Lett; 1990; 24(1):43-7. PubMed ID: 1695611 [TBL] [Abstract][Full Text] [Related]
10. Indirect allorecognition of major histocompatibility complex allopeptides in human renal transplant recipients with chronic graft dysfunction. Vella JP; Spadafora-Ferreira M; Murphy B; Alexander SI; Harmon W; Carpenter CB; Sayegh MH Transplantation; 1997 Sep; 64(6):795-800. PubMed ID: 9326400 [TBL] [Abstract][Full Text] [Related]
11. NY-ESO-1 119-143 is a promiscuous major histocompatibility complex class II T-helper epitope recognized by Th1- and Th2-type tumor-reactive CD4+ T cells. Zarour HM; Maillere B; Brusic V; Coval K; Williams E; Pouvelle-Moratille S; Castelli F; Land S; Bennouna J; Logan T; Kirkwood JM Cancer Res; 2002 Jan; 62(1):213-8. PubMed ID: 11782380 [TBL] [Abstract][Full Text] [Related]
12. Vaccination with recombinant NY-ESO-1 protein elicits immunodominant HLA-DR52b-restricted CD4+ T cell responses with a conserved T cell receptor repertoire. Bioley G; Dousset C; Yeh A; Dupont B; Bhardwaj N; Mears G; Old LJ; Ayyoub M; Valmori D Clin Cancer Res; 2009 Jul; 15(13):4467-74. PubMed ID: 19531622 [TBL] [Abstract][Full Text] [Related]
13. Class I peptides involved in the indirect pathway of allorecognition. Takemoto SK Clin Transpl; 1997; ():317-35. PubMed ID: 9919415 [TBL] [Abstract][Full Text] [Related]
14. Altered peptide ligands of islet autoantigen Imogen 38 inhibit antigen specific T cell reactivity in human type-1 diabetes. Geluk A; van Meijgaarden KE; Roep BO; Ottenhoff TH J Autoimmun; 1998 Aug; 11(4):353-61. PubMed ID: 9776713 [TBL] [Abstract][Full Text] [Related]
15. Identification of naturally processed T cell epitopes from glutamic acid decarboxylase presented in the context of HLA-DR alleles by T lymphocytes of recent onset IDDM patients. Endl J; Otto H; Jung G; Dreisbusch B; Donie F; Stahl P; Elbracht R; Schmitz G; Meinl E; Hummel M; Ziegler AG; Wank R; Schendel DJ J Clin Invest; 1997 May; 99(10):2405-15. PubMed ID: 9153283 [TBL] [Abstract][Full Text] [Related]
16. Structure-based discovery of nonpeptidic small organic compounds to block the T cell response to myelin basic protein. Koehler NK; Yang CY; Varady J; Lu Y; Wu XW; Liu M; Yin D; Bartels M; Xu BY; Roller PP; Long YQ; Li P; Kattah M; Cohn ML; Moran K; Tilley E; Richert JR; Wang S J Med Chem; 2004 Oct; 47(21):4989-97. PubMed ID: 15456243 [TBL] [Abstract][Full Text] [Related]
17. Analysis of antigen-specific T-cell responses with synthetic peptides--what kind of peptide for which purpose? Kiecker F; Streitz M; Ay B; Cherepnev G; Volk HD; Volkmer-Engert R; Kern F Hum Immunol; 2004 May; 65(5):523-36. PubMed ID: 15172453 [TBL] [Abstract][Full Text] [Related]
18. Induction of EBV-latent membrane protein 1-specific MHC class II-restricted T-cell responses against natural killer lymphoma cells. Kobayashi H; Nagato T; Takahara M; Sato K; Kimura S; Aoki N; Azumi M; Tateno M; Harabuchi Y; Celis E Cancer Res; 2008 Feb; 68(3):901-8. PubMed ID: 18245493 [TBL] [Abstract][Full Text] [Related]
19. Induction of human cytotoxic T lymphocytes by artificial antigen-presenting cells. Latouche JB; Sadelain M Nat Biotechnol; 2000 Apr; 18(4):405-9. PubMed ID: 10748520 [TBL] [Abstract][Full Text] [Related]
20. Augmentation of immune response by an analog of the antigenic peptide in a human T-cell clone recognizing mutated Ras-derived peptides. Yokomizo H; Matsushita S; Fujisao S; Murakami S; Fujita H; Shirouzu M; Yokoyama S; Ogawa M; Nishimura Y Hum Immunol; 1997 Jan; 52(1):22-32. PubMed ID: 9021406 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]